Rep. Kevin Hern Sells Off Shares of Novartis AG (NYSE:NVS)

29 Sep 2026, 20:02 by Amy Steele · The Cerbat Gem

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Novartis AG (NYSE:NVS). In a filing disclosed on September 25th, the Representative disclosed that they had sold between $15,001 and $50,000 in Novartis stock on August 27th. The trade occurred in the Representative’s “KEVIN HERN TRADITIONAL IRA” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $15,001 – $50,000 in shares of CenterPoint Energy (NYSE:CNP) on 9/15/2026.
Sold $1,001 – $15,000 in shares of TJX Companies (NYSE:TJX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of STERIS (NYSE:STE) on 9/15/2026.
Sold $1,001 – $15,000 in shares of Seagate Technology (NASDAQ:STX) on 9/15/2026.
Sold $15,001 – $50,000 in shares of NextEra Energy (NYSE:NEE) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Marsh & McLennan Companies (NYSE:MRSH) on 9/14/2026.
Sold $15,001 – $50,000 in shares of IQVIA (NYSE:IQV) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 9/14/2026.
Sold $15,001 – $50,000 in shares of Emerson Electric (NYSE:EMR) on 9/14/2026.

Novartis Stock Performance

NVS traded down $1.32 on Tuesday, hitting $145.56. The company’s stock had a trading volume of 1,598,487 shares, compared to its average volume of 1,999,275. Novartis AG has a 12 month low of $121.57 and a 12 month high of $170.46. The firm has a market cap of $277.75 billion, a P/E ratio of 21.95, a price-to-earnings-growth ratio of 2.81 and a beta of 0.45. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.89. The company’s 50 day simple moving average is $151.45 and its 200-day simple moving average is $151.08.

Novartis (NYSE:NVS – Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported $2.41 earnings per share (EPS) for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. The business had revenue of $14.95 billion for the quarter. Analysts forecast that Novartis AG will post 8.87 EPS for the current year.

Hedge Funds Weigh In On Novartis

A number of large investors have recently modified their holdings of NVS. J.W. Cole Advisors Inc. boosted its holdings in shares of Novartis by 0.6% in the fourth quarter. J.W. Cole Advisors Inc. now owns 10,577 shares of the company’s stock worth $1,348,000 after buying an additional 64 shares during the last quarter. Roundview Capital LLC raised its holdings in shares of Novartis by 2.5% during the 4th quarter. Roundview Capital LLC now owns 2,711 shares of the company’s stock worth $374,000 after acquiring an additional 66 shares in the last quarter. CPC Advisors LLC raised its holdings in shares of Novartis by 4.6% during the 2nd quarter. CPC Advisors LLC now owns 1,516 shares of the company’s stock worth $238,000 after acquiring an additional 66 shares in the last quarter. IMA Advisory Services Inc. boosted its position in shares of Novartis by 10.9% during the 4th quarter. IMA Advisory Services Inc. now owns 710 shares of the company’s stock valued at $98,000 after acquiring an additional 70 shares during the last quarter. Finally, Moody National Bank Trust Division grew its holdings in shares of Novartis by 4.2% in the second quarter. Moody National Bank Trust Division now owns 1,802 shares of the company’s stock valued at $282,000 after purchasing an additional 72 shares in the last quarter. 13.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. Jefferies Financial Group restated a “neutral” rating on shares of Novartis in a research note on Thursday, July 23rd. Bank of America reissued a “buy” rating on shares of Novartis in a report on Tuesday, September 8th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novartis in a research note on Sunday, August 9th. HSBC upgraded shares of Novartis from a “reduce” rating to a “hold” rating and increased their target price for the stock from $123.00 to $136.00 in a research note on Thursday, September 10th. Finally, UBS Group restated a “neutral” rating on shares of Novartis in a research report on Thursday, September 17th. Six analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $148.40.

Check Out Our Latest Stock Report on NVS

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Novartis Company Profile

(Get Free Report)

Novartis AG is a Switzerland-based pharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company’s research and commercial activities center on cardiovascular, renal and metabolic diseases, immunology, neuroscience, oncology and hematology. Its portfolio includes prescription medicines such as Entresto, Cosentyx, Kesimpta, Kisqali, Pluvicto, Leqvio and Jakavi, as well as other therapies for serious and chronic conditions.